Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease‐related symptoms in patients with myelofibrosis (MF). However, no clear survival benefit has been demonstrated, which may in part reflect suboptimal drug expo...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Med
Hoofdauteurs: Pugliese, Novella, Giordano, Claudia, Nappi, Davide, Luciano, Luigiana, Cerchione, Claudio, Annunziata, Mario, Casale, Beniamino, Crisà, Elena, Villa, Maria Rosaria, Pezzullo, Luca, Iovine, Maria, Picardi, Marco, Grimaldi, Francesco, Pane, Fabrizio, Martinelli, Vincenzo
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2019
Onderwerpen:
Clinical Cancer Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6558489/
https://ncbi.nlm.nih.gov/pubmed/30997748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2147
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items